Abstract: Background: Treating tardive dyskinesia (TD) with anticholinergics is a common practice, despite the lack of supportive evidence and potential to worsen TD.
Methods: Eight move...
Abstract: Background: Valbenazine is a once-daily VMAT2 inhibitor approved for the treatment of tardive dyskinesia (TD). Data from a 48-week, open-label study of valbenazine (KINECT 4 [NC...
Abstract: Background: In clinical trials of valbenazine, which is approved for once-daily treatment of tardive dyskinesia (TD), psychiatric stability was assessed along with global change...